{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:06:49Z","timestamp":1790251609652,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005363","name":"Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["20020150100054BA"],"award-info":[{"award-number":["20020150100054BA"]}],"id":[{"id":"10.13039\/501100005363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"CONICET","doi-asserted-by":"publisher","award":["PIP 112201 501003 00CO"],"award-info":[{"award-number":["PIP 112201 501003 00CO"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacl.2026.08.018","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:01:19Z","timestamp":1788188479000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab enhances HDL functionality in rheumatoid arthritis: A 6-month prospective study on cardiovascular risk modulation"],"prefix":"10.1016","author":[{"given":"Leonardo","family":"G\u00f3mez Rosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-4015","authenticated-orcid":false,"given":"Eliana","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Soledad S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Davico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo","family":"Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-6169","authenticated-orcid":false,"given":"Ignacio","family":"Gandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol","family":"Kontush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0161-164X","authenticated-orcid":false,"given":"Fernando","family":"Brites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jacl.2026.08.018_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2023.09.004","article-title":"The cardiovascular burden of rheumatoid arthritis - implications for treatment","volume":"136","author":"Schattner","year":"2023","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2026.08.018_bib2","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.018_bib3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.41613","article-title":"Divergence of cardiovascular biomarkers of lipids and subclinical myocardial injury among rheumatoid arthritis patients with increased inflammation","volume":"73","author":"Weber","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"45","key":"10.1016\/j.jacl.2026.08.018_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035912","article-title":"Meta-analysis of risk factors for cardiovascular disease in patients with rheumatoid arthritis","volume":"102","author":"Lyu","year":"2023","journal-title":"Med (Baltim)"},{"issue":"8","key":"10.1016\/j.jacl.2026.08.018_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237072","article-title":"Cardiovascular risk in persons at risk of developing rheumatoid arthritis","volume":"15","author":"van Boheemen","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.018_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jamainternmed.2023.3087","article-title":"Aortic stenosis risk in rheumatoid arthritis","volume":"183","author":"Johnson","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.018_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/pr.58.3.1","article-title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis","volume":"58","author":"Kontush","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.018_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/CIRCULATIONAHA.119.041658","article-title":"Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study","volume":"141","author":"Soria-Florido","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jacl.2026.08.018_bib9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","article-title":"High-density lipoprotein revisited: biological functions and clinical relevance","volume":"44","author":"von Eckardstein","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.018_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11883-025-01308-9","article-title":"High-density lipoprotein particle composition, functionality, deficiency, and atherosclerotic cardiovascular disease risk: a review","volume":"27","author":"Schaefer","year":"2025","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"10.1016\/j.jacl.2026.08.018_bib11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41569-021-00538-z","article-title":"High-density lipoproteins, reverse cholesterol transport and atherogenesis","volume":"18","author":"Pownall","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"23","key":"10.1016\/j.jacl.2026.08.018_bib12","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.120.044221","article-title":"HDL in the 21st century: a multifunctional roadmap for future HDL research","volume":"143","author":"Rohatgi","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.018_bib13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/antiox14040430","article-title":"How does HDL participate in atherogenesis? Antioxidant activity versus role in reverse cholesterol transport","volume":"14","author":"Durrington","year":"2025","journal-title":"Antioxid (Basel)"},{"issue":"12","key":"10.1016\/j.jacl.2026.08.018_bib14","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.molmed.2020.07.005","article-title":"HDL and reverse remnant-cholesterol transport (RRT): relevance to cardiovascular disease","volume":"26","author":"Kontush","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jacl.2026.08.018_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1470488","article-title":"Update on tocilizumab in rheumatoid arthritis: a narrative review","volume":"16","author":"Parisi","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.018_bib16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.atherosclerosis.2014.09.034","article-title":"Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation","volume":"237","author":"G\u00f3mez Rosso","year":"2014","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacl.2026.08.018_bib17","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jacl.2026.08.018_bib18","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/jcm9072157","article-title":"Anti-atherogenic modification of serum lipoprotein function in patients with rheumatoid arthritis after tocilizumab treatment, a pilot study","volume":"9","author":"Greco","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.jacl.2026.08.018_bib19","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/antiox11122317","article-title":"Association between paraoxonase\/arylesterase activity of serum PON-1 enzyme and rheumatoid arthritis: a systematic review and meta-analysis","volume":"11","author":"Erre","year":"2022","journal-title":"Antioxid (Basel)"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.018_bib20","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.018_bib21","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.018_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/ATVBAHA.112.300979","article-title":"Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels","volume":"33","author":"Villard","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"10.1016\/j.jacl.2026.08.018_bib23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1177\/2047487319894114","article-title":"Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease","volume":"27","author":"Feng","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.018_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1161\/01.ATV.13.6.815","article-title":"Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects","volume":"13","author":"Lagrost","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.018_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0003-2697(89)90424-7","article-title":"Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase\/arylesterase","volume":"180","author":"Furlong","year":"1989","journal-title":"Anal Biochem"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.018_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.11095","article-title":"Tocilizumab monotherapy or combined with methotrexate for rheumatoid arthritis","volume":"8","author":"Liu","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacl.2026.08.018_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956795","article-title":"Interleukin-6 inhibition in the treatment of autoinflammatory diseases","volume":"13","author":"Koga","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.018_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jacl.2026.08.018_bib29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.018_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.018_bib31","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.018_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1440-1746.2010.06560.x","article-title":"Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis","volume":"26","author":"Zhao","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jacl.2026.08.018_bib33","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","article-title":"Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis","volume":"76","author":"Robertson","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.018_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.018_bib35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.018_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jacl.2026.08.018_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.018_bib38","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.08.018_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000001136","article-title":"Obicetrapib: a novel cholesterol ester transfer protein inhibitor","author":"Maalizadeh","year":"2025","journal-title":"Cardiol Rev"},{"issue":"12","key":"10.1016\/j.jacl.2026.08.018_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.125.327271","article-title":"CETP inhibitors: back with a new target","volume":"138","author":"Nicholls","year":"2026","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.018_bib41","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-021-00304-0","article-title":"Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study","volume":"8","author":"Pierini","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.018_bib42","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/art.39675","article-title":"Effect of drug therapy on net cholesterol efflux capacity of high-density lipoprotein-enriched serum in rheumatoid arthritis","volume":"68","author":"Ormseth","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.018_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/a-0833-4627","article-title":"Effect of IL-6 receptor blockade on proprotein convertase subtilisin\/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients","volume":"51","author":"Ferraz-Amaro","year":"2019","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.018_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.mol.0000226116.35555.eb","article-title":"Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages","volume":"17","author":"Jessup","year":"2006","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.018_bib45","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1194\/jlr.M054510","article-title":"Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART","volume":"56","author":"El Khoury","year":"2015","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.018_bib46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa0907687","article-title":"Genetic variant of the scavenger receptor BI in humans","volume":"364","author":"Vergeer","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jacl.2026.08.018_bib47","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/ATVBAHA.109.194548","article-title":"Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent","volume":"29","author":"Larrede","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.018_bib48","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/STROKEAHA.121.034393","article-title":"U-shaped relationship of high-density lipoprotein cholesterol and incidence of total, ischemic and hemorrhagic stroke: a prospective cohort study","volume":"53","author":"Li","year":"2022","journal-title":"Stroke"},{"issue":"25","key":"10.1016\/j.jacl.2026.08.018_bib49","first-page":"00630","article-title":"Association between high-density lipoprotein cholesterol and the risk of cardiovascular disorders: a cohort study of healthy adults","volume":"S0002-9149","author":"Park","year":"2025","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.018_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","article-title":"Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors","volume":"31","author":"Chapman","year":"2010","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.018_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0021-9150(99)00452-9","article-title":"Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels","volume":"152","author":"Brites","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.08.018_bib52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbacli.2017.07.002","article-title":"Antioxidative activity of high-density lipoprotein (HDL): mechanistic insights into potential clinical benefit","volume":"8","author":"Brites","year":"2017","journal-title":"BBA Clin"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.018_bib53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00129784-200404040-00002","article-title":"The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention","volume":"4","author":"Mackness","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.018_bib54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"10.1016\/j.jacl.2026.08.018_bib55","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1111\/bph.15272","article-title":"LDL receptors, caveolae and cholesterol in endothelial dysfunction: oxLDLs accomplices or victims?","volume":"178","author":"Luchetti","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacl.2026.08.018_bib56","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.5551\/jat.RV22042","article-title":"Beyond high-density lipoprotein-cholesterol: unraveling the complexity of high-density lipoprotein functionality","volume":"32","author":"Endo","year":"2025","journal-title":"J Atheroscler Thromb"},{"issue":"10","key":"10.1016\/j.jacl.2026.08.018_bib57","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.immuni.2025.09.012","article-title":"Inflammation in atherosclerosis: lessons and therapeutic implications","volume":"58","author":"Libby","year":"2025","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.018_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39833","article-title":"Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial","volume":"69","author":"Charles-Schoeman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacl.2026.08.018_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.765749","article-title":"Improvements in high-density lipoprotein quantity and quality contribute to the cardiovascular benefits by anti-tumor necrosis factor therapies in rheumatoid arthritis: a systemic review and meta-analysis","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.018_bib60","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jacl.2017.02.018","article-title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project","volume":"11","author":"Garc\u00eda-G\u00f3mez","year":"2017","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:26:45Z","timestamp":1790249205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"alternative-id":["S1933287426004927"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.018","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab enhances HDL functionality in rheumatoid arthritis: A 6-month prospective study on cardiovascular risk modulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}